# Eva De Lago

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 41 papers | 1,871 citations | 257357 24 h-index | 289141 40 g-index |
| 42 all docs | 42 docs citations | 42 times ranked | 1922 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | TDP-43 Modulation by Tau-Tubulin Kinase 1 Inhibitors: A New Avenue for Future Amyotrophic Lateral Sclerosis Therapy. Journal of Medicinal Chemistry, 2022, 65, 1585-1607. | 2.9 | 20 |
| 2 | Targeting nuclear protein TDP-43 by cell division cycle kinase 7 inhibitors: A new therapeutic approach for amyotrophic lateral sclerosis. European Journal of Medicinal Chemistry, 2021, 210, 112968. | 2.6 | 26 |
| 3 | Recent advances in the pathogenesis and therapeutics of amyotrophic lateral sclerosis. British Journal of Pharmacology, 2021, 178, 1253-1256. | 2.7 | 3 |
| 4 | Retinal Ganglion Cell Loss and Microglial Activation in a SOD1G93A Mouse Model of Amyotrophic Lateral Sclerosis. International Journal of Molecular Sciences, 2021, 22, 1663. | 1.8 | 8 |
| 5 | Targeting the CB<sub>2</sub> receptor and other endocannabinoid elements to delay disease progression in amyotrophic lateral sclerosis. British Journal of Pharmacology, 2021, 178, 1373-1387. | 2.7 | 13 |
| 6 | Inactivation of the CB<sub>2</sub> receptor accelerated the neuropathological deterioration in TDPâ€43 transgenic mice, a model of amyotrophic lateral sclerosis. Brain Pathology, 2021, 31, e12972. | 2.1 | 13 |
| 7 | Tideglusib, a Non-ATP Competitive Inhibitor of GSK-3Î² as a Drug Candidate for the Treatment of Amyotrophic Lateral Sclerosis. International Journal of Molecular Sciences, 2021, 22, 8975. | 1.8 | 24 |
| 8 | BiP Heterozigosity Aggravates Pathological Deterioration in Experimental Amyotrophic Lateral Sclerosis. International Journal of Molecular Sciences, 2021, 22, 12533. | 1.8 | 5 |
| 9 | Preclinical Investigation in Neuroprotective Effects of the GPR55 Ligand VCE-006.1 in Experimental Models of Parkinsonâ€™s Disease and Amyotrophic Lateral Sclerosis. Molecules, 2021, 26, 7643. | 1.7 | 10 |
| 10 | Motor neuron preservation and decrease of in vivo TDP-43 phosphorylation by protein CK-1Î´ kinase inhibitor treatment. Scientific Reports, 2020, 10, 4449. | 1.6 | 44 |
| 11 | Pharmacokinetics of SativexÂ® in Dogs: Towards a Potential Cannabinoid-Based Therapy for Canine Disorders. Biomolecules, 2020, 10, 279. | 1.8 | 24 |
| 12 | Targeting glial cannabinoid <scp>CB<sub>2</sub></scp> receptors to delay the progression of the pathological phenotype in <scp>TDPâ€43</scp> (<scp>A315T</scp>) transgenic mice, a model of amyotrophic lateral sclerosis. British Journal of Pharmacology, 2019, 176, 1585-1600. | 2.7 | 46 |
| 13 | Analysis of endocannabinoid receptors and enzymes in the post-mortem motor cortex and spinal cord of amyotrophic lateral sclerosis patients. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 377-386. | 1.1 | 20 |
| 14 | Neuroprotective effects of the cannabigerol quinone derivative VCE-003.2 in SOD1G93A transgenic mice, an experimental model of amyotrophic lateral sclerosis. Biochemical Pharmacology, 2018, 157, 217-226. | 2.0 | 45 |
| 15 | Up-regulation of CB2 receptors in reactive astrocytes in canine degenerative myelopathy, a disease model of amyotrophic lateral sclerosis. DMM Disease Models and Mechanisms, 2017, 10, 551-558. | 1.2 | 46 |
| 16 | A <scp>S</scp>ativex<sup>Â®</sup>â€like combination of phytocannabinoids as a diseaseâ€modifying therapy in a viral model of multiple sclerosis. British Journal of Pharmacology, 2015, 172, 3579-3595. | 2.7 | 58 |
| 17 | Endocannabinoids and amyotrophic lateral sclerosis. , 2015, , 99-123. | | 9 |
| 18 | The disease-modifying effects of a Sativex-like combination of phytocannabinoids in mice with experimental autoimmune encephalomyelitis are preferentially due to Î”-tetrahydrocannabinol acting through CB1 receptors. Multiple Sclerosis and Related Disorders, 2015, 4, 505-511. | 0.9 | 30 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Changes in the endocannabinoid signaling system in CNS structures of TDP-43 transgenic mice: relevance for a neuroprotective therapy in TDP-43-related disorders. Journal of NeuroImmune Pharmacology, 2015, 10, 233-244. | 2.1 | 44 |
| 20 | Changes in Endocannabinoid Receptors and Enzymes in the Spinal Cord of <scp>SOD</scp>1<sup>G93A</sup> Transgenic Mice and Evaluation of a Sativex<sup>Â®</sup>â€like Combination of Phytocannabinoids: Interest for Future Therapies in Amyotrophic Lateral Sclerosis. CNS Neuroscience and Therapeutics, 2014, 20, 809-815. | 1.9 | 54 |
| 21 | Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects. Neuropharmacology, 2012, 62, 2299-2308. | 2.0 | 70 |
| 22 | Identification of receptors and enzymes for endocannabinoids in NSC-34 cells: Relevance for in vitro studies with cannabinoids in motor neuron diseases. Neuroscience Letters, 2012, 508, 67-72. | 1.0 | 13 |
| 23 | Endocannabinoid regulation of spinal nociceptive processing in a model of neuropathic pain. European Journal of Neuroscience, 2010, 31, 1414-1422. | 1.2 | 27 |
| 24 | The endocannabinoid system as a target for the treatment of neuronal damage. Expert Opinion on Therapeutic Targets, 2010, 14, 387-404. | 1.5 | 78 |
| 25 | Cannabinoids, multiple sclerosis and neuroprotection. Expert Review of Clinical Pharmacology, 2009, 2, 645-660. | 1.3 | 13 |
| 26 | Cannabinoids and Neuroprotection in Motor-Related Disorders. CNS and Neurological Disorders - Drug Targets, 2007, 6, 377-387. | 0.8 | 43 |
| 27 | Neurochemical effects of the endocannabinoid uptake inhibitor UCM707 in various rat brain regions. Life Sciences, 2007, 80, 979-988. | 2.0 | 9 |
| 28 | Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: Importance of antioxidant and cannabinoid receptor-independent properties. Brain Research, 2007, 1134, 162-170. | 1.1 | 258 |
| 29 | Cannabinoids and Neuroprotection in Basal Ganglia Disorders. Molecular Neurobiology, 2007, 36, 82-91. | 1.9 | 79 |
| 30 | UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders. European Neuropsychopharmacology, 2006, 16, 7-18. | 0.3 | 70 |
| 31 | Effects of inhibition of fatty acid amide hydrolase vs. the anandamide membrane transporter on TRPV1-mediated calcium responses in adult DRG neurons; the role of CB1receptors. European Journal of Neuroscience, 2006, 24, 3489-3495. | 1.2 | 18 |
| 32 | Acyl-based anandamide uptake inhibitors cause rapid toxicity to C6 glioma cells at pharmacologically relevant concentrations. Journal of Neurochemistry, 2006, 99, 677-688. | 2.1 | 27 |
| 33 | Effect of repeated systemic administration of selective inhibitors of endocannabinoid inactivation on rat brain endocannabinoid levels. Biochemical Pharmacology, 2005, 70, 446-452. | 2.0 | 81 |
| 34 | Arvanil, a hybrid endocannabinoid and vanilloid compound, behaves as an antihyperkinetic agent in a rat model of Huntington's disease. Brain Research, 2005, 1050, 210-216. | 1.1 | 37 |
| 35 | Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis. Neurobiology of Disease, 2005, 20, 207-217. | 2.1 | 131 |
| 36 | In vivo pharmacological actions of two novel inhibitors of anandamide cellular uptake. European Journal of Pharmacology, 2004, 484, 249-257. | 1.7 | 92 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Involvement of vanilloid-like receptors in the effects of anandamide on motor behavior and nigrostriatal dopaminergic activity: in vivo and in vitro evidence. Brain Research, 2004, 1007, 152-159. | 1.1 | 91 |
| 38 | Design, synthesis and biological evaluation of new endocannabinoid transporter inhibitors. European Journal of Medicinal Chemistry, 2003, 38, 403-412. | 2.6 | 42 |
| 39 | Design, Synthesis, and Biological Evaluation of New Inhibitors of the Endocannabinoid Uptake:â€‰ Comparison with Effects on Fatty Acid Amidohydrolase. Journal of Medicinal Chemistry, 2003, 46, 1512-1522. | 2.9 | 83 |
| 40 | UCM707, a potent and selective inhibitor of endocannabinoid uptake, potentiates hypokinetic and antinociceptive effects of anandamide. European Journal of Pharmacology, 2002, 449, 99-103. | 1.7 | 63 |
| 41 | STR data for nine Y-chromosomal loci. Forensic Science International, 2002, 127, 142-144. | 1.3 | 4 |